CAR-T Cell Therapy in India: Cost, Hospitals & Eligibility Explained

Many patients struggle with relapsed or refractory blood cancers, and they seek treatments internationally. In search of advanced therapies, patients and their families often choose CAR-T cell therapy in India. Along with carrying the emotional weight of the diagnosis, comparing hospitals, understanding complex medical terms, evaluating costs, arranging travel, and making sure they are choosing the right specialists becomes draining. Every decision feels critical, especially when time is limited, and the next course of treatment could determine the outcome. In such moments, having access to trusted medical guidance and coordinated support can make the journey far less overwhelming and help families move forward with greater confidence.

Let's explore the availability of this treatment in India’s top hospitals and how to make the treatment process stress-free.

CAR-T cell therapy (Chimeric Antigen Receptor T-cell therapy) is an advanced form of immunotherapy that uses a patient's own immune cells to recognize and fight certain types of cancer. As opposed to chemotherapy or radiation, which directly attack cancer cells, CAR-T therapy enhances the body's natural immune response by modifying T cells to identify and destroy the affected cells better. The process starts with T-cell collection, in which immune cells are separated from the patient's blood via leukapheresis. Then, these cells are genetically modified to recognize cancer cells and infused back into the patient’s bloodstream to attack the cancer cells.

It is primarily recommended for people with certain blood cancers that returned after treatment or did not respond to standard therapies. Before considering this therapy, every patient must undergo comprehensive evaluations by a multidisciplinary team.

Patients who may be eligible include:

• People with specific blood cancers, such as B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), certain other B-cell lymphomas, and multiple myeloma 

• Patients whose cancer has relapsed or not responded to previous treatments, including chemotherapy, targeted therapy, and immunotherapy.    

• Patients whose cancer cells express the target antigen (such as CD19 or BCMA), which allows the engineered CAR-T cells to recognize and attack the cancer effectively. 

• Individuals who are medically fit after the doctor’s assessment, including organ function, existing medical conditions, and the patient's ability to tolerate the therapy and its potential side effects. 

Through decades of research, CAR-T treatment was first developed in the United States and Europe. Over the years, it gained approvals from the concerned authorities and is now used worldwide. Today, this treatment is also available in selected cancer hospitals in India. In addition to this, India achieved another milestone with the development of NexCAR19, India’s first homegrown CAR-T cell therapy, developed by ImmunoACT, a biotechnology company incubated at IIT Bombay, in collaboration with clinicians and researchers at Tata Memorial Centre. Since receiving approval in 2023, it has been introduced at selected specialized cancer centers across India, where eligible patients can receive treatment under the supervision of multidisciplinary oncology teams.

One of the major reasons international patients choose India for this treatment is access to advanced oncology care and multidisciplinary expertise at an affordable rate.

Some of the leading CAR-T therapy hospitals in India include:

• Indraprastha Apollo Hospital, New Delhi 

• Fortis Memorial Research Institute, Gurugram 

• BLK-Max Super Speciality Hospital, New Delhi 

• Medanta – The Medicity, Gurugram 

• Artemis Hospital, Gurugram 

• Max Super Speciality Hospital, Saket, New Delhi 

• Apollo Cancer Centre, Chennai 

• Apollo Hospital, Ahmedabad 

• Apollo Hospitals, Jubilee Hills, Hyderabad 

• Amrita Hospital, Faridabad 

• Apollo Hospital, Bannerghatta, Bengaluru 

• Apollo Hospitals, Navi Mumbai 

• Apollo Multispeciality Hospital, Kolkata 

Here is the estimated total treatment cost (USD) per patient. It is important to note that these figures are indicative ranges and vary by CAR-T product (domestically developed vs. imported branded therapies), hospital, disease type, and length of ICU/inpatient stay.

Procedure	India	UAE	USA	Turkey	UK
CAR-T cell therapy	$30K–90K	$60K–100K+	$400K–1M+	$40K–50K	$350K–500K

Since this therapy is not yet widely available in Kenyan hospitals, many patients prefer to go abroad for treatment. India has emerged as a preferred destination because it offers a shorter and more convenient journey from Nairobi than many Western countries, supported by well-established flight connections. In addition to the treatment infrastructure, the cost of CAR-T cell therapy in India is significantly lower than in the US or Europe. Indian hospitals also have extensive experience treating patients from Kenya and across Africa. Above all, in India, patients get reliable assistance from medical facilitators who coordinate care for patients, covering travel and accommodation arrangements, visa assistance and interpreter support.

Even though international patients are aware of the quality and affordability of cancer care in India, choosing a hospital that is reliable and cheaper than in their country often becomes challenging. Further, arranging a medical visa, travel, accommodation, and other treatment logistics on their own adds another layer of stress during an already challenging time. This is where PrymaCare Tourismo, a Government of India-registered medical tourism company, steps in to simplify the entire treatment coordination process. This includes connecting patients with the best hospitals for CAR-T therapy in India, arranging consultations with experienced oncologists, coordinating second opinions, assisting with medical visas and travel, and supporting patients throughout their treatment journey. In addition, patients receive 24/7 personalized assistance, multilingual language support, seamless coordination between hospitals and the attendees, continued follow-up care after treatment, and zero-commission services, ensuring they receive home-like care and dedicated support throughout.

CAR-T cell therapy in India has opened new possibilities and hope for patients with relapsed or treatment-resistant blood cancers by giving access to advanced treatment, experienced oncology teams, and internationally recognized hospitals. While every patient's eligibility and treatment goals are different, choosing the right hospital and ensuring seamless coordination are essential parts of the journey. PrymaCare Tourismo simplifies this process by connecting international patients with leading CAR-T therapy hospitals in India, coordinating all the treatment-related procedures from the initial consultation through follow-up care. With expert medical guidance and end-to-end support, patients and their families can approach treatment decisions with greater clarity and confidence.

Take the next step toward advanced cancer care and contact PrymaCare Tourismo for personalized assistance.